



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.usplo.gov

Fax Cover Sheet

Date: 10 Dec 2003 To: Mr. Herink From: Irene Marx Application/Control Number: 09/753,381 Art Unit: 1651 Phone No.: 703-308-2922 Fax No.: (515) 243-0654 **Return Fax No.:** 703-872-9306 Voice No.: CC: Re: advisory action copy requested Urgent **For Review For Comment For Reply** Per Your Request Comments: The action is attached

Number of pages $\frac{5}{2}$ including this page

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450





UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/753,381	01/02/2001	Eddy Van Beek	4532670/44892		
75	90 09/03/2003				
Kent A. Herink, Esq. Davis, Brown, Koehn, Shors & Roberts, P.C. The Financial Center			EXAMINER MARX, IRENE		
,,			1651		
			DATE MAILED: 09/03/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No. Applicant(s)					
) '	Advisory Action	09/753,381	BEEK ET AL.				
	navicery nauch	Examiner	Art Unit				
		Irene Marx	1651				
	The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence addr	ess			
Theret final re condit	REPLY FILED 12 August 2003 FAILS TO PLACE To fore, further action by the applicant is required to a selection under 37 CFR 1.113 may only be either: (1) ion for allowance; (2) a timely filed Notice of Appear nation (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applicated a timely filed amendment which	ation. A proper reply n places the applicat	to a ion in			
	PERIOD FOR RE	EPLY [check either a) or b)]					
a) [
, –	The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH	g date of the final rejectio HE FINAL REJECTION. S	n. See MPEP			
fee have fee und (2) as s	tensions of time may be obtained under 37 CFR 1.136(a). The been filed is the date for purposes of determining the period of er 37 CFR 1.17(a) is calculated from: (1) the expiration date of et forth in (b) above, if checked. Any reply received by the Office led, may reduce any earned patent term adjustment. See 37 C	of extension and the corresponding amo the shortened statutory period for reply the later than three months after the mail	unt of the fee. The appro originally set in the final C	opriate extension Office action; or			
1.	. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:							
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) ⊠ they raise the issue of new matter (see Note below);							
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
(d	(d) they present additional claims without canceling a corresponding number of finally rejected claims.						
	NOTE: see attachment.						
3.	Applicant's reply has overcome the following reject	ion(s):					
4.	Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed a	amendment			
5.🛛	The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for application in condition for allowance because: see		dered but does NOT	place the			
6.	The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were	newly			
7.	For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			nd an			
	The status of the claim(s) is (or will be) as follows:						
	Claim(s) allowed:						
	Claim(s) objected to:						
	Claim(s) rejected: <u>1-7</u> .		• •				
	Claim(s) withdrawn from consideration: <u>8-9</u> .	•					
8.							
	Note the attached Information Disclosure Statemer						
	9. Note the attached information disclosure statement(s)(1 10-1443)1 aper 10(s).						
۔ ⊶.							
			Irene Marx Primary Examiner Art Unit: 1651				
			, 11. 0.111. 1001				



Art Unit: 1651

Note:

The proposed amendment raises new issues that would require further consideration and/or search with respect to the amendments to the specification wherein "Relative NDF breakdown" is proposed to be replaced by "Percent NDF remaining", including issues of new matter.

Response to Arguments

Applicant's arguments have been fully considered but they are not deemed to be persuasive.

Applicants argue that Table II shows that lysolecithin shows the breakdown of neutral detergent fiber to be the most effective an breaking down NDF at 89.80%. Applicants also assert that "Relative NDF breakdown" really means "Percent NDF remaining". However, there is no clear evidence to demonstrate this assertion. In addition, even if Table II were shown to be correct as alleged, the data merely would show that a specific composition containing 16% of Bolec MT, which contains an undefined proportion of lysolecithin is useful to enhance the effectiveness of a specific xylanase in a specific application and not any enzyme as now claimed. The actual amount of "lysolecithins" used to obtain the touted results is not disclosed, and in any event, the claims do not require a specific amount, except for claims 6 and 7.

The scope of the showing must be commensurate with the scope of claims to consider evidence probative of unexpected results, for example. In re Dill, 202 USPQ 805 (CCPA, 1979), In re Lindner 173 USPQ 356 (CCPA 1972), In re Hyson, 172 USPQ 399 (CCPA 1972), In re Boesch, 205 USPQ 215, (CCPA 1980), In re Grasselli, 218 USPQ 769 (Fed. Cir. 1983), In re Clemens, 206 USPQ 289 (CCPA 1980). It should be clear that the probative value of the data is not commensurate in scope with the degree of protection sought by the claim.

Therefore the rejection is deemed proper and it is adhered to.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (703) 308-2922. The examiner can normally be reached on Monday through Friday from 6:30 AM to 3:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The appropriate fax phone number for the organization where this application or proceeding is assigned is before final (703) 872-9306 and after final, (703) 872-9307.

Page 3

Application/Control Number: 09/753,381

Art Unit: 1651

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Customer Service whose telephone number is (703) 308-0198 or the receptionist whose telephone number is (703) 308-1235. There many

Irene Marx

Primary Examiner

Art Unit 1651